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Abstract
Background: The cholesteryl ester transfer protein (CETP) polymorphism I405V has been suggested to be
involved in longevity and susceptibility to cardiovascular diseases. An enhanced reverse cholesterol transport
due to enhanced HDL levels has been hypothesized to be the underlying mechanism. However, clinical trials
with HDL-enhancing drugs failed to show beneficial effects. Consequently, it has been postulated that genetic
variations enhancing HDL levels are cardioprotective only if they also decrease LDL levels.
Methods: A cross-sectional study was conducted to genotype 1028 healthy blood donors and 1517 clinically
well characterized elderly for CETP I405V.
Results: We could not find any association of this polymorphism with age for both, males or females, in any
of these cohorts (P = 0.71 and P = 0.57, respectively, for males and P = 0.55 and P = 0.88, respectively, for
females). In addition, no association with cardiovascular diseases could be observed in the elderly cohort
(males OR = 1.12 and females OR = 0.88). In the same cohort, the CETP V405V genotype was associated with
significantly enhanced HDL levels (P = 0.03), mostly owing to the female sex (P = 0.46 for males, P = 0.02 for
females), whereas LDL and triglyceride levels were unchanged (P = 0.62 and P = 0.18, respectively).
Conclusion: Our data support the recent hypothesis that variations enhancing HDL levels without affecting
LDL levels are not associated with the risk for cardiovascular diseases.
Keywords: Cholesteryl ester transfer protein, Genetic polymorphism, High-density lipoprotein, Single
nucleotide polymorphism, Cardio vascular disease
Background
The process of aging and longevity are complex and far
from being understood. Besides lifestyle and environmental
factors, numerous genetic factors have been proposed to in-
fluence these processes. Several studies showed that healthy
aging and particularly longevity, known as aging up to 90
years or more, are highly heritable. For example, siblings of
centenarians also have an enhanced probability for a longer
healthy life [1, 2]. In addition to variations of mitochondrial
and nuclear DNA, also the composition of gut microbiome
has been suggested to play an important role for longevity
[3]. Variations of nuclear DNA that have been postulated to
be associated with aging phenotypes include polymor-
phisms of genes encoding proteins of the immune system
[4], the DNA repair system, particularly variations affecting
telomere length [5, 6], metabolism [7, 8], and variations as-
sociated with the onset of age-related diseases such as ath-
erosclerosis resulting in cardiovascular diseases (CVD),
diabetes mellitus, Alzheimer Disease, and cancer [9].
Among age-associated diseases, CVD plays a pivotal role
regarding mortality in the middle-aged population of the
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Western world [10, 11]. Next to lifestyle, the most accepted
risk factor for atherosclerosis is dyslipidemia and high chol-
esterol levels (reviewed by Steinberg [12–15]). Plasma chol-
esterol is bound to lipoproteins such as low density (LDL)
and high density (HDL) lipoproteins. LDL transports chol-
esterol into cells, whereas HDL-bound cholesterol is trans-
ported to the liver for excretion [16]. The correlation of
high cholesterol levels and the susceptibility to CVD led to
the development and wide use of cholesterol-lowering
drugs, among them the statins, which result in a decreased
LDL level [15]. On the other hand, high HDL levels have
been found to be protective against CVD [17], supporting
the “Reverse Cholesterol Transport” (RCT) concept, ac-
cording to which HDL-mediated cholesterol transport to
the liver results in its fecal excretion and, thereby, in the re-
duction of plasma cholesterol level [18].
Notably, susceptibility for atherosclerosis shows a strong
genetic basis [19, 20]. Several genome-wide association
studies have been conducted identifying many risk vari-
ants for this condition. As expected, some of these vari-
ants affect the lipid metabolism (reviewed by Prins et al.
[21]). A unique “lipoprotein genotype”, defined by varia-
tions affecting the lipid metabolism, including several
polymorphisms in lipoprotein transfer genes, has been
suggested to be associated with longevity [22]. Among
them, the apolipoprotein E polymorphisms rs429358 and
rs7412 determining the three major alleles E2, E3, and E4
of apoE [23, 24], polymorphisms in cholesteryl ester trans-
fer protein (CETP, rs5882) and apolipoprotein CIII
(rs2542052) have been shown to influence lipid metabol-
ism and to be associated with age [22, 25, 26].
CETP is a plasma protein that catalyzes the transfer of
cholesteryl ester from HDL to other lipoproteins. A point
mutation resulting in a splicing defect of CETP pre-mRNA
causes a loss of plasma CETP. Subjects homozygous for
this mutation exhibit significantly elevated HDL levels
[27]. In line with the “Reverse Cholesterol Transport
(RCT)” concept, CETP inhibition was hypothesized to be a
strategy to increase HDL levels and thereby lowering
plasma cholesterol levels and reducing susceptibility for
atherosclerosis [28, 29]. Therefore, several CETP inhibitors
have been tested in clinical trials. However, a recent meta-
analysis revealed that elevation of HDL levels failed to in-
duce a significant benefit regarding protection from ath-
erosclerosis. It was suggested then that elevation of HDL
levels alone does not result in an increased RCT rate [30].
Another hypothetical explanation for this failure is that
HDL levels are rather a marker or a consequence of CVD
without being causally involved in CVD pathogenesis [31].
The CETP SNP rs5882 (I405V) V/V variant has been
shown to reduce CETP levels and, according to the RCT
hypothesis, should be cardio-protective and, conse-
quently, associated with longevity [32]. However, con-
flicting results have been published showing the V/V
genotype to be either positively associated with longevity
in a Jewish population or negatively associated in an
Asian population [25, 26, 33]. Apart from longevity,
which accounts only for a small part of aging pheno-
types, healthy aging up to 70–90 years is another im-
portant parameter, since the human population rapidly
ages. We here investigated the association of the CETP
rs5882 (I405V) SNP with healthy aging and the suscepti-
bility to cardiovascular disease in two study groups, the
first group consisting of healthy blood donors from
Lithuania and a second study group from Poland con-




Blood of 1028 healthy voluntary unrelated blood donors
was obtained during the years 2008–2012 at the Na-
tional Blood Center (Kaunas, Lithuania). All participants
were of Caucasian ethnicity and were free of chronic dis-
ease or permanent medication use. This cohort has been
instrumental previously for hemochromatosis gene HFE
studies [34]. Genotyping was successful in 989 samples.
Polish cohort
PolSenior was a multicenter, interdisciplinary project, de-
signed to assess health and socio-economic status of the
Polish Caucasians aged ≥65 years. In short, study partici-
pants, recruited using three-stage stratified proportional
draw, were split into equally-sized age groups (65–69, 70–
74, 75–79, 80–84, 85–89 and ≥90 years). Details of the
PolSenior recruitment are described elsewhere [35]. Pro-
ject participants completed a detailed questionnaire re-
garding their medical, social, and economic past and
current status, underwent an examination including ele-
ments of comprehensive geriatric assessment, and do-
nated blood for biochemical and genetic analyses. A sub-
group of 1517 participants of the PolSenior program, the
first ones for whom the complete medical records (includ-
ing, among others, data on cardiovascular and respiratory
diseases, cancer, diabetes, stroke and cognitive impair-
ment) and DNA samples were available at the beginning
of current study, was analyzed.
Genotyping
Genomic DNA was prepared by standard salting-out pro-
cedures. The genetic analysis of the CETP rs5882 (I405V)
was performed by PCR employing the LightCyler 480™
(Roche Diagnostics) and subsequent melting curve ana-
lysis. The PCR reaction contained fluorescence-labeled
hybridization FRET probes. Primer and probes were as fol-
lows: f-primer: ctccagggaggactcacca, r-primer: cccctccagcc-
cacactta, anchor probe: LC640-cctgcagtcaatg-atcaccgctgt,
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sensor probe: tccgagtccatccagagct-FL resulting in melting
points of 54 °C and 61 °C for the wild-type (V), and the
mutated allele (I), respectively.
Statistics
P-values were determined by Chi2 test, in case of linear
or logistic regression P-values were determined by t-test or
Wald statistic, respectively. Linear and binary logistic re-
gression analyses have been performed by employing the
IBM SPSS Statistics software package (version 20.0, IBM,
Munich, Germany). The association of CETP genotypes
with age within the Lithuanian cohort was done by linear
regression with age as dependent variable (normality of the
data was assessed using a normality test) and genotypes as
independent variable. The association of CETP genotypes
with cardio vascular disease was analyzed by logistic regres-
sion with cardiovascular disease as dependent variable and
genotypes and age as independent variables. Association of
CETP genotypes with lipid levels were done age adjusted
with lipid levels as outcome variables and genotype as inde-
pendent variable. Age and lipid levels showed a linear asso-
ciation (data not shown), however, there was no change of
lipid levels with age. HDL and LDL levels were normally
distributed, only triglyceride levels showed a slight deviation
from normal distribution as determined by normality test.
Results
No association of CETP rs5882 with age
Baseline characteristic of genotyped subjects are shown
in Table 1. Results of genotyping for CETP rs5882
(I405V) indicate that an equal distribution of the geno-
types comparing younger (age < 50, mean age: 37.4, SD:
7.3) and older study subjects (age ≥ 50, mean age: 58.4,
SD: 7.7, Table 2) cannot be ruled out. The cut-off was
set at 50 years because the incidence of age-related dis-
eases significantly increases after this age. Since sex is
the most accepted factor associated with longevity, with
females reaching a significantly higher mean age than
males, we stratified our groups for sex. After this stratifi-
cation we also failed to find any significant association
with age by linear regression analysis, by comparing the
V/V genotype versus I/I + I/V genotypes for both, males
(P = 0.71) and females (P = 0.55).
In addition, we analyzed the group composed of 1517
Polish Caucasians, covering age 65 to 92, for an associ-
ation of the CETP V/V genotype with age. Also in this
cohort, we failed to detect any association of this SNP
with age in both males (P = 0.57) and females (P = 0.88)
(Table 3).
No association of CETP rs5882 with cardiovascular disease
In order to analyze the association of the CETP rs5882
(I405V) SNP with the occurrence of cardiovascular dis-
eases, we analyzed the 1517 PolSenior study participants,
for whom detailed medical reports were available. Com-
parison of the genotypes between subjects with cardio-
vascular diseases (mean age: 76.8 years) and disease-free
subjects (mean age: 76.7years) revealed only marginal
differences in the genotype distribution with V/V in sub-
jects with CVD and disease free subjects of 7.2 % and
7.6 %, respectively. By logistic regression comparing the
I/I + I/V versus V/V genotypes for males and females we
failed to reveal any significant associations (males: OR:
Table 1 Baseline characteristics of study subjects
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Male/Female 609/380 494/242 115/138






Disease free (%) 508 (33.5)
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DM (%) 121 (8.0)
MMSE Polish version of the mini-mental state examination test, DM
diabetes mellitus































The P-value for comparison of the three genotypes was determined by Chi2
Table 3 No associations of the CETP rs5882 V/V genotype with
age
Male Female
P-value B 95 % CI P-value B 95 % CI
Lithuanian cohort
V/V versus I/I + I/V 0.71 −0.02 −1.63–1.11 0.55 −0.03 −2.80–1.49
PolSenior group
V/V versus I/I + I/V 0.57 −0.02 −1.06–0.59 0.88 −0.15 −0.99–0.85
Association of age with genotypes was performed by univariate linear
regression comparing the less functional homozygote genotype with the
others (recessive model). The I/I + I/V genotypes were used as reference
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1.12, females: OR: 0.80). The co-variable age is also not
significantly associated with cardiovascular disease
(males: OR: 1.01, females: OR: 1.00) (Table 4).
Association of lipid levels with CETP rs5882 genotypes in
the PolSenior group
Since it has been postulated that CETP rs5882 (I405V)
genotypes influence HDL levels thereby potentially influ-
encing the risk of cardiovascular diseases [32], we ana-
lyzed lipid levels according to CETP genotypes in the
PolSenior group. Subjects with cardiovascular diseases
were excluded due to lipid lowering therapy. As ex-
pected, the CETP V/V genotype resulted in an age-
adjusted significantly enhanced HDL level (P = 0.03).
This increased HDL level was more pronounced and sig-
nificant in females (P = 0.02), and noticeable but not sig-
nificant in males (P = 0.46). No significant changes in
LDL and triglyceride levels could be observed (P = 0.62
and P = 0.18, respectively, Table 5). The low r2 values for
all associations indicate that genotypes as well as age as
co-variable has low impact on lipid levels. Analyzing
lipid levels in different age groups (65–74 years, 75–84
years, and 85–95 years) by Kruskal Wallis test also
showed no significant association (data not shown).
Discussion
An association of the CETP rs5882 (I405V) SNP with
longevity and aging-related morbidity has been pub-
lished with different results, suggesting the V/V genotype
to be protective in one study, or a risk factor in others
for example for CVD [25, 26, 33]. The hypothesized
mechanism is that elevated HDL levels found in subjects
with the V/V genotype may protect from CVD and
therefore result in a positive association of this genotype
with healthy aging and longevity [22]. Here we investi-
gated a cohort of middle aged healthy subjects and a
population-based cohort of aged subjects exhibiting the
typical distribution of age-related diseases, for an associ-
ation of CETP I405V with age and CVD. Although we
found a significantly enhanced HDL level in CETP 405
V/V carriers, we failed to find any association of this
genotype with age or CVD for both males and females.
A limitation of our study is the limited sample size,
therefore, we cannot rule out any effect of the CETP
I405V genotype on CVD or an association with age.
One potential explanation of this discrepancy between
our and some of the previously published studies may be
the different genetic background of the study popula-
tions. On the other hand, however, our negative results
may also reflect recent findings suggesting that HDL
levels may be a risk marker, but not a causal risk factor
for CVD [36]. Several other variants in genes affecting
lipid metabolism associated with elevated HDL levels
failed to display any association with CVD, with the
Table 4 No association of the CETP rs5882 V/V genotype with
cardiovascular disease within the PolSenior group
OR CI (95 %)
Female
CETP 405 V/V versus I/I + I/V 0.80 0.40–1.60
Age 1.00 0.96–1.02
Male
CETP 405 V/V versus I/I + I/V 1.12 0.62–2.02
Age 1.01 0.99–1.04
Odds ratios (OR) for cardiovascular disease were determined by logistic
regression with disease status as dependent variable and the genotypes as
independent variable. The combined I/I and I/V genotypes were used as
reference, and the V/V genotype as predictor. Age was included as co-variable
Table 5 Association of the CETP rs5882 V/V genotype with lipid levels
All I/I + I/V (n = 937) V/V (n = 77) P-value r2
HDL mean mg/dl (SD) 50.3 (13.2) 53.8 (17.0) 0.03 0.007
LDL mean mg/dl (SD) 126.4 (38.3) 128.9 (42.6) 0.62 0.005
Triglycerides mean mg/dl (SD) 128.4 (58.1) 138.5 (91.4) 0.18 0.010
Female I/I + I/V (n = 464) V/V (n = 39) P-value r2
HDL mean mg/dl (SD) 51.7 (12.9) 56.9 (16.5) 0.02 0.011
LDL mean mg/dl (SD) 129.2 (40.8) 132.8 (44.5) 0.94 0.001
Triglycerides mean mg/dl (SD) 138.7 (60.6) 145.1 (86.2) 0.56 0.007
Male I/I + I/V (n = 473) V/V (n = 38) P-value r2
HDL mean mg/dl (SD) 48.8 (13.3) 50.7 (17.3) 0.46 0.009
LDL mean mg/dl (SD) 123.6 (35.6) 124.9 (40.6) 0.92 0.024
Triglycerides mean mg/dl (SD) 118.3 (40.8) 131.9 (97.2) 0.19 0.018
Age-adjusted P-values were determined by linear regression. Subjects with cardiovascular diseases were excluded due to lipid lowering therapy. r2 = coefficient of
determination, SD = standard deviation, significant values are shown bold
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exception of those SNPs that were also associated with
decreased LDL or triglycerides levels. One example is
the CETP promoter SNP rs3764261. This SNP results,
in addition to elevated HDL levels, in decreased LDL
and triglyceride levels and is, therefore, associated with a
decreased risk for CVD [31]. Our results showed that
the CETP rs5882 (I405V) was associated with a signifi-
cantly elevated HDL level. LDL or triglyceride levels,
however, were unchanged. Therefore, the lack of any as-
sociation with CVD in our study is in agreement with
the results of other studies analyzing other HDL-
elevating SNPs that do not change LDL or triglyceride
levels [31]. In line with this, two recent trials testing the
HDL-elevating drugs niacin and dalceptrapib were ter-
minated prematurely because no clinical benefit could
be observed in subjects with established CVD [36]. Even
the reported association of CETP rs5882 (I405V) with
healthy aging or longevity should be taken with care,
particularly since the hypothesized mechanism of pro-
tection from CVD could not be confirmed. However,
our study is too small and needs larger confirmation
studies to exclude any association of CETP rs5882
(I405V) with healthy aging and, furthermore, other than
the described above mechanisms could be responsible
for such an association.
Conclusion
In our cohort we could not find evidence for an associ-
ation of CETP rs5882 (I405V) with CVD or LDL levels.
This is in line with the current hypothesis that only
SNPs affecting LDL levels or both, LDL and HDL levels,
protect from CVD. In line, we also failed to find an asso-
ciation of the HDL-increasing genotype of CETP rs5882
(I405V) with aging not complicated by CVD.
Abbreviations
CETP, cholesteryl ester transfer protein; CVD, cardio vascular disease; FRET,
fluorescence resonance energy transfer; HDL, high density lipoprotein; LDL,
low density lipoprotein; RCT, reverse cholesterol transfer
Acknowledgement
We thank Inga Wyroslak for outstanding technical assistance.
Funding
Financial support was provided by Charité - Universitätsmedizin Berlin (grant
2007-486), the Berliner Krebsgesellschaft e.V. (all to R.R.S), and by the Polish
Ministry of Science and Higher Education grant PBZ-MEiN-9/2/2006 – K143/
P01/2007/1 (MPK and MS).
Availability of data and material
Blinded genotyping data will be available on request.
Authors’ contributions
JB: genotyping, data analysis, AS: genotyping, JK + JS: sampling Lithuanian
cohort, LI: study design, MS: sampling Polish cohort, CK: statistics, RS: study
design, MP: study design, sampling Polish cohort, writing the manuscript, LH:
genotyping, data analysis, study design and writing the manuscript. All
authors’ read and approved the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethical approval and consent to participate
The study was approved by the Lithuanian Bioethics committee (Protocol
No. 2/2008) and the Bioethics Commission of the Medical University of
Silesia in Katowice (Protocol No. NN-6501/1/08). All participants gave a writ-
ten, informed consent for participation in the study. All investigations were
furthermore carried out in accordance with the ethical guidelines of the
1975 Declaration of Helsinki.
Author details
1Institute of Microbiology and Hygiene, Charité University Medical Center
Berlin, Rahel-Hirsch-Weg 3, 10117 Berlin, Germany. 2Research Institute of
Epidemiology, MOH, Yerevan, Armenia. 3Department of Gastro-enterology,
Lithuanian University of Health Sciences, Kaunas, Lithuania. 4Institute for
Digestive Research, Lithuanian University of Health Sciences, Kaunas,
Lithuania. 5Cellecta Inc, Mountain View, California, USA. 6Department of
Human Epigenetics, Mossakowski Medical Research Centre, Polish Academy
of Sciences, Warsaw, Poland. 7Department of Geriatrics and Gerontology,
Medical Centre of Postgraduate Education, Warsaw, Poland.
Received: 3 May 2016 Accepted: 14 July 2016
References
1. Atzmon G, Schechter C, Greiner W, Davidson D, Rennert G, Barzilai N.
Clinical phenotype of families with longevity. J Am Geriatr Soc. 2004;52(2):
274–7.
2. Perls TT, Wilmoth J, Levenson R, Drinkwater M, Cohen M, Bogan H, Joyce E,
Brewster S, Kunkel L, Puca A. Life-long sustained mortality advantage of
siblings of centenarians. Proc Natl Acad Sci U S A. 2002;99(12):8442–7.
3. Garagnani P, Pirazzini C, Giuliani C, Candela M, Brigidi P, Sevini F, Luiselli D,
Bacalini MG, Salvioli S, Capri M, et al. The three genetics (nuclear DNA,
mitochondrial DNA, and gut microbiome) of longevity in humans
considered as metaorganisms. Biomed Res Int. 2014;2014:560340.
4. Cevenini E, Monti D, Franceschi C. Inflamm-ageing. Curr Opin Clin Nutr
Metab Care. 2013;16(1):14–20.
5. Soerensen M, Dato S, Tan Q, Thinggaard M, Kleindorp R, Beekman M,
Jacobsen R, Suchiman HE, de Craen AJ, Westendorp RG, et al. Human
longevity and variation in GH/IGF-1/insulin signaling, DNA damage
signaling and repair and pro/antioxidant pathway genes: cross sectional
and longitudinal studies. Exp Gerontol. 2012;47(5):379–87.
6. Kim S, Bi X, Czarny-Ratajczak M, Dai J, Welsh DA, Myers L, Welsch MA,
Cherry KE, Arnold J, Poon LW, et al. Telomere maintenance genes SIRT1 and
XRCC6 impact age-related decline in telomere length but only SIRT1 is
associated with human longevity. Biogerontology. 2012;13(2):119–31.
7. Bonafe M, Barbieri M, Marchegiani F, Olivieri F, Ragno E, Giampieri C,
Mugianesi E, Centurelli M, Franceschi C, Paolisso G. Polymorphic variants of
insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase
genes affect IGF-I plasma levels and human longevity: cues for an
evolutionarily conserved mechanism of life span control. J Clin Endocrinol
Metab. 2003;88(7):3299–304.
8. Willcox BJ, Donlon TA, He Q, Chen R, Grove JS, Yano K, Masaki KH, Willcox
DC, Rodriguez B, Curb JD. FOXO3A genotype is strongly associated with
human longevity. Proc Natl Acad Sci U S A. 2008;105(37):13987–92.
9. Barzilai N, Shuldiner AR. Searching for human longevity genes: the future
history of gerontology in the post-genomic era. J Gerontol A Biol Sci Med
Sci. 2001;56(2):M83–87.
10. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J,
Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235
causes of death for 20 age groups in 1990 and 2010: a systematic analysis
for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–
128.
11. Niccoli T, Partridge L. Ageing as a risk factor for disease. Curr Biol. 2012;
22(17):R741–752.
Bustami et al. BMC Geriatrics  (2016) 16:144 Page 5 of 6
12. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An
interpretive history of the cholesterol controversy: part I. J Lipid Res. 2004;
45(9):1583–93.
13. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An
interpretive history of the cholesterol controversy: part II: the early evidence
linking hypercholesterolemia to coronary disease in humans. J Lipid Res.
2005;46(2):179–90.
14. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis: an
interpretive history of the cholesterol controversy, part III: mechanistically
defining the role of hyperlipidemia. J Lipid Res. 2005;46(10):2037–51.
15. Steinberg D. The pathogenesis of atherosclerosis. An interpretive history of
the cholesterol controversy, part IV: the 1984 coronary primary prevention
trial ends it–almost. J Lipid Res. 2006;47(1):1–14.
16. Brown MS, Kovanen PT, Goldstein JL. Regulation of plasma cholesterol by
lipoprotein receptors. Science. 1981;212(4495):628–35.
17. Emerging Risk Factors C, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S,
Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, et al. Major lipids,
apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000.
18. Rosenson RS, Brewer Jr HB, Davidson WS, Fayad ZA, Fuster V, Goldstein J,
Hellerstein M, Jiang XC, Phillips MC, Rader DJ, et al. Cholesterol efflux and
atheroprotection: advancing the concept of reverse cholesterol transport.
Circulation. 2012;125(15):1905–19.
19. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic
susceptibility to death from coronary heart disease in a study of twins. N
Engl J Med. 1994;330(15):1041–6.
20. Zdravkovic S, Wienke A, Pedersen NL, Marenberg ME, Yashin AI, De Faire U.
Heritability of death from coronary heart disease: a 36-year follow-up of 20
966 Swedish twins. J Intern Med. 2002;252(3):247–54.
21. Prins BP, Lagou V, Asselbergs FW, Snieder H, Fu J. Genetics of coronary
artery disease: genome-wide association studies and beyond.
Atherosclerosis. 2012;225(1):1–10.
22. Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, Lipton R, Cheng
S, Shuldiner AR. Unique lipoprotein phenotype and genotype associated
with exceptional longevity. JAMA. 2003;290(15):2030–40.
23. Chaudhary R, Likidlilid A, Peerapatdit T, Tresukosol D, Srisuma S,
Ratanamaneechat S, Sriratanasathavorn C. Apolipoprotein E gene
polymorphism: effects on plasma lipids and risk of type 2 diabetes and
coronary artery disease. Cardiovasc Diabetol. 2012;11:36.
24. Deelen J, Beekman M, Uh HW, Helmer Q, Kuningas M, Christiansen L, Kremer
D, van der Breggen R, Suchiman HE, Lakenberg N, et al. Genome-wide
association study identifies a single major locus contributing to survival into
old age; the APOE locus revisited. Aging Cell. 2011;10(4):686–98.
25. Atzmon G, Rincon M, Schechter CB, Shuldiner AR, Lipton RB, Bergman A,
Barzilai N. Lipoprotein genotype and conserved pathway for exceptional
longevity in humans. PLoS Biol. 2006;4(4):e113.
26. Vergani C, Lucchi T, Caloni M, Ceconi I, Calabresi C, Scurati S, Arosio B. I405V
polymorphism of the cholesteryl ester transfer protein (CETP) gene in
young and very old people. Arch Gerontol Geriatr. 2006;43(2):213–21.
27. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR. HDL from CETP-deficient
subjects shows enhanced ability to promote cholesterol efflux from
macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest.
2006;116(5):1435–42.
28. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y,
Mabuchi H, Tall AR. Increased high-density lipoprotein levels caused by a
common cholesteryl-ester transfer protein gene mutation. N Engl J Med.
1990;323(18):1234–8.
29. Inazu A, Jiang XC, Haraki T, Yagi K, Kamon N, Koizumi J, Mabuchi H, Takeda
R, Takata K, Moriyama Y, et al. Genetic cholesteryl ester transfer protein
deficiency caused by two prevalent mutations as a major determinant of
increased levels of high density lipoprotein cholesterol. J Clin Invest. 1994;
94(5):1872–82.
30. Hourcade-Potelleret F, Laporte S, Lehnert V, Delmar P, Benghozi R, Torriani
U, Koch R, Mismetti P. Clinical benefit from pharmacological elevation of
high-density lipoprotein cholesterol: meta-regression analysis. Heart. 2015;
101(11):847–53.
31. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M,
Jensen MK, Hindy G, Holm H, Ding EL, Johnson T, et al. Plasma HDL
cholesterol and risk of myocardial infarction: a mendelian randomisation
study. Lancet. 2012;380(9841):572–80.
32. Bruce C, Sharp DS, Tall AR. Relationship of HDL and coronary heart disease
to a common amino acid polymorphism in the cholesteryl ester transfer
protein in men with and without hypertriglyceridemia. J Lipid Res. 1998;
39(5):1071–8.
33. Sun L, Hu CY, Shi XH, Zheng CG, Huang ZZ, Lv ZP, Huang J, Wan G, Qi KY,
Liang SY, et al. Trans-ethnical shift of the risk genotype in the CETP I405V
with longevity: a Chinese case–control study and meta-analysis. PLoS One.
2013;8(8):e72537.
34. Kucinskas L, Juzenas S, Sventoraityte J, Cedaviciute R, Vitkauskiene A,
Kalibatas V, Kondrackiene J, Kupcinskas L. Prevalence of C282Y, H63D, and
S65C mutations in hereditary HFE-hemochromatosis gene in Lithuanian
population. Ann Hematol. 2012;91(4):491–5.
35. Bledowski P, Mossakowska M, Chudek J, Grodzicki T, Milewicz A, Szybalska A,
Wieczorowska-Tobis K, Wiecek A, Bartoszek A, Dabrowski A, et al. Medical,
psychological and socioeconomic aspects of aging in Poland: assumptions
and objectives of the PolSenior project. Exp Gerontol. 2011;46(12):1003–9.
36. Rader DJ, Tall AR. The not-so-simple HDL story: Is it time to revise the HDL
cholesterol hypothesis? Nat Med. 2012;18(9):1344–6.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Bustami et al. BMC Geriatrics  (2016) 16:144 Page 6 of 6
